April 26, 2019 06:37 AM EDT

Nine listings and $3.8B later, HKEX celebrates one-year biotech anniversary with $194M CRO IPO

Amber Tong

So how is Hong Kong stock exchange’s biotech board doing one year after regulators opened up the listing regime to pre-revenue companies in the field …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Nine listings and $3.8B later, HKEX celebrates one-year biotech anniversary with $194M CRO IPO

Amber Tong

Sign up to read this article for free.

Judge halts some NIH cuts after 22 states sue

Merck KGaA confirms interest in acquiring cancer biotech SpringWorks

Decade after $8B deal, Roche offloads InterMune to mysterious specialty pharma

Eli Lilly inks $630M deal for Phase 1 MASH candidate

Boehringer Ingelheim touts success in second Phase 3 lung fibrosis trial

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Nine list­ings and $3.8B lat­er, HKEX cel­e­brates one-year biotech an­niver­sary with $194M CRO IPO

Amber Tong

Sign up to read this article for free.

Judge halts some NIH cuts af­ter 22 states sue

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

Decade af­ter $8B deal, Roche of­floads In­ter­Mune to mys­te­ri­ous spe­cial­ty phar­ma

Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date

Boehringer In­gel­heim touts suc­cess in sec­ond Phase 3 lung fi­bro­sis tri­al

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

Nine listings and $3.8B later, HKEX celebrates one-year biotech anniversary with $194M CRO IPO

Judge halts some NIH cuts after 22 states sue

Merck KGaA confirms interest in acquiring cancer biotech SpringWorks

Decade after $8B deal, Roche offloads InterMune to mysterious specialty pharma

Eli Lilly inks $630M deal for Phase 1 MASH candidate

Boehringer Ingelheim touts success in second Phase 3 lung fibrosis trial

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers